

Garth William Rapeport

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5169900/publications.pdf>

Version: 2024-02-01

52
papers

2,005
citations

331259

21
h-index

315357

38
g-index

54
all docs

54
docs citations

54
times ranked

1682
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Safety and Antiviral Effects of Nebulized PC786 in a Respiratory Syncytial Virus Challenge Study. <i>Journal of Infectious Diseases</i> , 2022, 225, 2087-2096. | 1.9 | 21 |
| 2 | Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults. <i>Nature Medicine</i> , 2022, 28, 1031-1041. | 15.2 | 281 |
| 3 | A Pandemic Lesson for Global Lung Diseases: Exacerbations Are Preventable. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 1271-1280. | 2.5 | 19 |
| 4 | <i>Pseudomonas aeruginosa</i> induces p38MAP kinase-dependent IL-6 and CXCL8 release from bronchial epithelial cells via a Syk kinase pathway. <i>PLoS ONE</i> , 2021, 16, e0246050. | 1.1 | 9 |
| 5 | SARS-CoV-2 Human Challenge Studies – Establishing the Model during an Evolving Pandemic. <i>New England Journal of Medicine</i> , 2021, 385, 961-964. | 13.9 | 39 |
| 6 | Safety and nonclinical and clinical pharmacokinetics of PC945, a novel inhaled triazole antifungal agent. <i>Pharmacology Research and Perspectives</i> , 2021, 9, e00690. | 1.1 | 38 |
| 7 | The role of antifungals in the management of patients with severe asthma. <i>Clinical and Translational Allergy</i> , 2020, 10, 46. | 1.4 | 22 |
| 8 | In vitro antifungal activity of a novel topical triazole PC945 against emerging yeast <i>Candida auris</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2943-2949. | 1.3 | 30 |
| 9 | Anti-fungal activity of a novel triazole, PC1244, against emerging azole-resistant <i>Aspergillus fumigatus</i> and other species of <i>Aspergillus</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2950-2958. | 1.3 | 12 |
| 10 | Antifungal synergy of a topical triazole, PC945, with a systemic triazole against respiratory <i>Aspergillus fumigatus</i> infection. <i>Scientific Reports</i> , 2019, 9, 9482. | 1.6 | 29 |
| 11 | Reduced Nasal Viral Load and IFN Responses in Infants with Respiratory Syncytial Virus Bronchiolitis and Respiratory Failure. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 1074-1084. | 2.5 | 73 |
| 12 | Late therapeutic intervention with a respiratory syncytial virus L-protein polymerase inhibitor, PC786, on respiratory syncytial virus infection in human airway epithelium. <i>British Journal of Pharmacology</i> , 2018, 175, 2520-2534. | 2.7 | 23 |
| 13 | <i>In Vitro</i> and <i>In Vivo</i> Efficacy of a Novel and Long-Acting Fungicidal Azole, PC1244, on <i>Aspergillus fumigatus</i> Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, . | 1.4 | 24 |
| 14 | G37(P) – Laboratory correlates of severity in acute bronchiolitis of infancy. , 2018, , . | | 0 |
| 15 | 1335. Safety and Pharmacokinetic Profile of PC786, a Novel Inhibitor of Respiratory Syncytial Virus L-protein Polymerase, in a Single and Multiple-Ascending Dose Study in Healthy Volunteer and Mild Asthmatics. <i>Open Forum Infectious Diseases</i> , 2018, 5, S407-S408. | 0.4 | 4 |
| 16 | Current approaches to the discovery of novel inhaled medicines. <i>Drug Discovery Today</i> , 2018, 23, 1705-1717. | 3.2 | 48 |
| 17 | <i>In Vitro</i> and <i>In Vivo</i> Antifungal Profile of a Novel and Long-Acting Inhaled Azole, PC945, on <i>Aspergillus fumigatus</i> Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, . | 1.4 | 60 |
| 18 | Discovery of novel benzothienazepine derivatives as potent inhibitors of respiratory syncytial virus. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 2201-2206. | 1.0 | 15 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | <i>In Vivo</i> Biomarker Analysis of the Effects of Intranasally Dosed PC945, a Novel Antifungal Triazole, on <i>Aspergillus fumigatus</i> Infection in Immunocompromised Mice. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, . | 1.4 | 19 |
| 20 | Nasosorption as a Minimally Invasive Sampling Procedure: Mucosal Viral Load and Inflammation in Primary RSV Bronchiolitis. <i>Journal of Infectious Diseases</i> , 2017, 215, 1240-1244. | 1.9 | 29 |
| 21 | Effects of intranasally dosed posaconazole on fungal load and biomarkers in <i>Aspergillus fumigatus</i> infected immunocompromised mice. <i>Mycoses</i> , 2017, 60, 728-735. | 1.8 | 4 |
| 22 | Preclinical Characterization of PC786, an Inhaled Small-Molecule Respiratory Syncytial Virus L Protein Polymerase Inhibitor. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, . | 1.4 | 30 |
| 23 | Anti-Viral Activities of PC786, a Novel Inhibitor of Respiratory Syncytial Virus L-Protein Polymerase. <i>Open Forum Infectious Diseases</i> , 2016, 3, . | 0.4 | 1 |
| 24 | In Vivo Biomarker Analysis of Intranasally Dosed PC945, a Novel Antifungal Agent, in <i>Aspergillus Fumigatus</i> Infection in Immunocompromised Mice. <i>Open Forum Infectious Diseases</i> , 2016, 3, . | 0.4 | 0 |
| 25 | Discovery of Narrow Spectrum Kinase Inhibitors: New Therapeutic Agents for the Treatment of COPD and Steroid-Resistant Asthma. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 1727-1746. | 2.9 | 19 |
| 26 | LATE-BREAKING ABSTRACT: Effects of a single treatment with PC786, a novel inhibitor of respiratory syncytial virus replication, on viral load and biomarkers in fully differentiated human bronchial epithelial cells. , 2016, , . | | 0 |
| 27 | 89 Superior effects of RV568, a narrow spectrum kinase inhibitor, on RSV infection in primary bronchial epithelial cells obtained from patients with cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2011, 10, S23. | 0.3 | 0 |
| 28 | 90 Inhibitory effects of RV1088, a novel narrow spectrum kinase inhibitor, on RSV infection in primary bronchial epithelial cells obtained from patients with cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2011, 10, S23. | 0.3 | 0 |
| 29 | Vitamin D And Narrow Spectrum Kinase Inhibitors Modulate Inflammatory Mediator Release In A Model Of Steroid-Insensitivity And Viral Exposure. , 2011, , . | | 0 |
| 30 | Superior Effects Of RV568, A Novel Narrow Spectrum Kinase Inhibitor, To BIRB796, A P38MAPK Inhibitor, On Pro-Inflammatory Cytokine Reduction In Macrophages. , 2011, , . | | 1 |
| 31 | Effects Of RV1088, A Narrow Spectrum Kinase Inhibitor, On Human Rhinovirus Replication And Cytokine Production. , 2011, , . | | 0 |
| 32 | Superior Effects Of RV1088, A Novel Narrow Spectrum Kinase Inhibitor, To BIRB796, A P38MAPK Inhibitor, On Pro-Inflammatory Cytokine Production In Macrophages. , 2011, , . | | 0 |
| 33 | Rhinovirus 16 (RV16) Induces Airway Hyper-Responsiveness And Release Of IL-8 And IP-10 From Human Small Airways, Which Is Modulated By Narrow Spectrum Kinase Inhibitors. , 2011, , . | | 0 |
| 34 | Effects Of RV568, A Narrow Spectrum Kinase Inhibitor, On Human Rhinovirus Replication And Cytokine Production. , 2011, , . | | 0 |
| 35 | RV1088, A Narrow Spectrum Kinase Inhibitor, Inhibits Steroid Resistant Viral Exacerbations Of Ovalbumin-Induced Allergic Airways Responses In Guinea-Pigs. , 2011, , . | | 0 |
| 36 | Inhibition Of Steroid Resistant Viral Exacerbations Of Ovalbumin-Induced Allergic Airways Responses In Guinea-Pigs By A Narrow Spectrum Kinase Inhibitor, RV568. , 2011, , . | | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Involvement Of P38MAPK Gamma On Corticosteroid Refractory Airway Inflammation Induced By Tobacco Smoke In Mice. , 2010, , . | | 0 |
| 38 | The influence of diet upon liver function tests and serum lipids in healthy male volunteers resident in a Phase I unit. British Journal of Clinical Pharmacology, 2003, 57, 199-208. | 1.1 | 72 |
| 39 | Combining fMRI with a Pharmacokinetic Model to Determine Which Brain Areas Activated by Painful Stimulation Are Specifically Modulated by Remifentanyl. NeuroImage, 2002, 16, 999-1014. | 2.1 | 175 |
| 40 | Enzyme-Induction Dependent Bioactivation of Troglitazone and Troglitazone Quinone In Vivo. Chemical Research in Toxicology, 2001, 14, 965-974. | 1.7 | 107 |
| 41 | An FMRI method to determine specific drug-induced modulations of functional activations using a pharmacokinetic model. NeuroImage, 2001, 13, 959. | 2.1 | 1 |
| 42 | A pharmacokinetic study of granisetron (BRL 43694A), a selective 5-HT3 receptor antagonist: correlation with anti-emetic response. Cancer Chemotherapy and Pharmacology, 1989, 24, 45-9. | 1.1 | 144 |
| 43 | Pharmacokinetics and anti-emetic efficacy of BRL43694, a new selective 5HT-3 antagonist. British Journal of Cancer, 1988, 58, 651-653. | 2.9 | 52 |
| 44 | Neuropharmacology of emesis induced by anti-cancer therapy. Trends in Pharmacological Sciences, 1988, 9, 334-341. | 4.0 | 319 |
| 45 | The serotonin type 3 receptor antagonist BRL 43694 and nausea and vomiting induced by cisplatin.. BMJ: British Medical Journal, 1988, 297, 110-111. | 2.4 | 57 |
| 46 | Clinical Pharmacokinetics of Allopurinol. Clinical Pharmacokinetics, 1986, 11, 343-353. | 1.6 | 109 |
| 47 | Factors Influencing the Relationship Between Carbamazepine Plasma Concentration and Its Clinical Effects in Patients with Epilepsy. Clinical Neuropharmacology, 1985, 8, 141-149. | 0.2 | 17 |
| 48 | Clinical Pharmacokinetics of Bretylium. Clinical Pharmacokinetics, 1985, 10, 248-256. | 1.6 | 19 |
| 49 | Variability of Phenytoin Protein Binding in Epilepsy. Archives of Neurology, 1984, 41, 363-363. | 4.9 | 1 |
| 50 | CARBAMAZEPINE-INDUCED NON-HEREDITARY ACUTE PORPHYRIA. Lancet, The, 1983, 321, 790-792. | 6.3 | 35 |
| 51 | Carbamazepine and Haem Biosynthesis in Man. Clinical Science, 1982, 63, 22P-23P. | 1.8 | 3 |
| 52 | Loop Diuretics - Infusion or Bolus?. Clinical Science, 1982, 63, 33P-34P. | 1.8 | 1 |